From NPR.

For users of the popular weight loss injectables Ozempic, Wegovy, Zepbound and Mounjaro, a new GLP-1 pill may be on the horizon.

GLP-1 drugs have revolutionized the way the doctors treat weight loss — starting largely with Ozempic — Novo Nordisk’s blockbuster diabetes drug. But most of the current options on the market are injectables, which can be intimidating for patients to use.

Eli Lilly announced Thursday that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants’ A1C — a measure of blood sugar control — better than a placebo.

The trial lasted 40 weeks and only involved people with Type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Mounjaro. The once-daily pill also helped patients lose up to 16 pounds.